Jocelyn Craparo, MD
Obstetrics · Bryn Mawr, PANPI 1407903495
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,132 and has fallen 51.6% since, to $547 in 2025.
Across 248 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$789
- Astellas Pharma US Inc$710
- Amgen$624
- Mayne Pharma Commercial LLC$293
- Sumitomo Pharma America, Inc.$286
- Aspira Women's Health Inc$284
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,90998%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $789 |
| Astellas Pharma US Inc | 29 | $710 |
| Amgen | 34 | $624 |
| Mayne Pharma Commercial LLC | 12 | $293 |
| Sumitomo Pharma America, Inc. | 10 | $286 |
| Aspira Women's Health Inc | 4 | $284 |
| Therapeuticsmd, Inc. | 14 | $252 |
| Pfizer | 14 | $230 |
| Myovant Sciences Inc. | 11 | $201 |
| Exeltis, USA Inc. | 10 | $194 |
| Mylan Pharmaceuticals Inc. | 8 | $145 |
| Bayer | 6 | $125 |
| Avion Pharmaceuticals | 8 | $123 |
| Daiichi Sankyo Inc. | 4 | $101 |
| Millicent US Inc | 5 | $98 |
| Coopersurgical, Inc. | 4 | $71 |
| Radius Health, Inc. | 4 | $56 |
| Shield Therapeutics Inc | 3 | $55 |
| Sage Therapeutics, LLC | 2 | $53 |
| Evofem Biosciences, Inc. | 3 | $49 |
| Renovia Inc | 2 | $41 |
| Urovant Sciences Inc | 2 | $40 |
| Hologic Sales And Service, LLC | 2 | $37 |
| Agile Therapeutics, Inc. | 1 | $30 |
| Eisai Inc. | 1 | $25 |
| Exact Sciences | 1 | $22 |
| Bausch Health US, LLC | 1 | $22 |
| Roche Diagnostics Corporation | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Mission Pharmacal Company | 1 | $17 |
| Scynexis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$125
- NEXTSTELLIS$114
How this compares
$5,024 in reported general payments places this provider in the 85th percentile of 36 obstetrics providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 309 | $26,748 |
| MyrbetriqMirabegron | 27 | $21,523 |
| PremarinEstrogens, Conjugated | 48 | $20,078 |
| YuvafemEstradiol | 82 | $14,698 |
| PremproEstrogen,con/M-Progest Acet | 17 | $11,402 |
| EstringEstradiol | 11 | $5,946 |
| Raloxifene Hcl | 56 | $3,602 |
| Estradiol (Twice Weekly)Estradiol | 18 | $2,639 |
| ProgesteroneProgesterone, Micronized | 60 | $2,466 |
| Betamethasone Valerate | 70 | $1,456 |
| ValacyclovirValacyclovir Hcl | 32 | $1,306 |
| Clobetasol Propionate | 55 | $1,164 |
| Ibandronate Sodium | 12 | $661 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $597 |
| Alendronate Sodium | 29 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro, Estring | $230 | $37,42676 claims |
| Astellas Pharma US IncMyrbetriq | $710 | $21,52327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 36 obstetrics providers in Pennsylvania.
Other obstetrics in Bryn Mawr
- Yarini QuezadaPhiladelphia$51K
- John DoughertyWest Reading$12K
- Holly ThomasHarrisburg$6K
- Stephanie BrownMc Murray$5K
- J TedescoScranton$3K
- Yun Lin ChengDrexel Hill$3K
- Christine KanskyWest Chester$2K
- Sara LangeDubois$2K
- Sarah WarnerErie$1K
- Theresa AcquaahGettysburg$933
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.